top of page
LATEST NEWS
Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
4 hours ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
18 hours ago3 min read


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
18 hours ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


Gene Therapy: A New Era for Diabetes Treatment
The fight against diabetes is being revolutionized with an innovative approach from Genprex, with its gene therapy candidate, GPX-002. Genprex, a gene therapy company focused on developing therapies for cancer and diabetic patients, has announced its plan to launch a new subsidiary, NewCo, which would solely focus on developing and commercializing GPX-002. GPX-002 was designed to treat both Type 1 and Type 2 Diabetes. This gene therapy employs an engineered AAV vector to deli
Sep 3, 2024


Penn Medicine Studies on AAV-based Gene Therapies Suggest Integration into Human DNA is Unlikely to Drive Cancer Mutations
Penn Medicine research offers promising insights into AAV-based gene therapies' safety: Integration into human DNA is unlikely to trigger cancer mutations. A recent study from the University of Pennsylvania’s Gene Therapy Program, published in Nature Biotechnology and Human Gene Therapy, analyzed AAV-based gene therapies in non-human primates. This study suggests that the integration of AAV vectors into chromosomal DNA, if it occurs, is unlikely to induce cancer-causing mutat
Mar 1, 2024
bottom of page


